Rheumatoid arthritis (RA) treatment has improved dramatically over the past two decades as further insight has been gained into the immune pathophysiology of this chronic joint disease that affects nearly 1.5 million people in the United States. Biologic therapy, including TNF inhibitors and several non-TNF targeted biologics, has allowed physicians to intervene earlier and enabled patients to achieve quicker relief, more productive lives, and better overall outcomes.